# A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

> **NCT06012812** · PHASE2 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 79 (actual)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** SHR-1819 injection

## Key facts

- **NCT ID:** NCT06012812
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-06
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-06-05
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06012812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06012812, "A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06012812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*